Latest EcoR1 Capital, LLC Stock Portfolio
EcoR1 Capital, LLC Performance:
2025 Q4: 27.12%YTD: 35.99%2024: -21.74%
Performance for 2025 Q4 is 27.12%, and YTD is 35.99%, and 2024 is -21.74%.
About EcoR1 Capital, LLC and 13F Hedge Fund Stock Holdings
EcoR1 Capital, LLC is a hedge fund based in San Francisco, CA. On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, EcoR1 Capital, LLC reported an equity portfolio of $2.2 Billions as of 31 Dec, 2025.
The top stock holdings of EcoR1 Capital, LLC are ZYME, ANAB, JAZZ. The fund has invested 27.4% of it's portfolio in ZYMEWORKS INC and 17.3% of portfolio in ANAPTYSBIO INC.
The fund managers got completely rid off UNIQURE NV (QURE), TANGO THERAPEUTICS INC (TNGX) and APELLIS PHARMACEUTICALS INC (APLS) stocks. They significantly reduced their stock positions in SURROZEN INC (SRZN), XENCOR INC (XNCR) and IMMUNOME INC (IMNM). EcoR1 Capital, LLC opened new stock positions in CG ONCOLOGY INC, VAXCYTE INC (PCVX) and MANNKIND CORP (MNKD). The fund showed a lot of confidence in some stocks as they added substantially to VOYAGER THERAPEUTICS INC (VYGR) and CENTESSA PHARMACEUTICALS PLC (CNTA).
The top stock holdings of EcoR1 Capital, LLC are ZYME, ANAB, JAZZ. The fund has invested 27.4% of it's portfolio in ZYMEWORKS INC and 17.3% of portfolio in ANAPTYSBIO INC.
The fund managers got completely rid off UNIQURE NV (QURE), TANGO THERAPEUTICS INC (TNGX) and APELLIS PHARMACEUTICALS INC (APLS) stocks. They significantly reduced their stock positions in SURROZEN INC (SRZN), XENCOR INC (XNCR) and IMMUNOME INC (IMNM). EcoR1 Capital, LLC opened new stock positions in CG ONCOLOGY INC, VAXCYTE INC (PCVX) and MANNKIND CORP (MNKD). The fund showed a lot of confidence in some stocks as they added substantially to VOYAGER THERAPEUTICS INC (VYGR) and CENTESSA PHARMACEUTICALS PLC (CNTA).
EcoR1 Capital, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that EcoR1 Capital, LLC made a return of 27.12% in the last quarter. In trailing 12 months, it's portfolio return was 35.99%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| cg oncology inc | 32,053,400 |
| zenas biopharma inc | 28,666,700 |
| structure therapeutics inc | 23,256,100 |
| vaxcyte inc | 20,763,000 |
| mannkind corp | 9,412,200 |
| evolus inc | 4,488,750 |
| ibio inc | 4,300,040 |
| mereo biopharma group plc | 3,273,790 |
New stocks bought by EcoR1 Capital, LLC
Additions
| Ticker | % Inc. |
|---|---|
| voyager therapeutics inc | 497 |
| centessa pharmaceuticals plc | 466 |
Additions to existing portfolio by EcoR1 Capital, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| surrozen inc | -93.33 |
| xencor inc | -47.09 |
| immunome inc | -30.00 |
EcoR1 Capital, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| tango therapeutics inc | -89,298,200 |
| uniqure nv | -232,836,000 |
| apellis pharmaceuticals inc | -78,009,100 |
| prime medicine inc | -8,550,030 |
| kura oncology inc | -7,721,620 |
| pepgen inc | -3,696,000 |
| avidity biosciences inc | -33,331,000 |
| alkermes plc | -15,000,000 |
EcoR1 Capital, LLC got rid off the above stocks
Sector Distribution
EcoR1 Capital, LLC has about 60% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 60 |
| Others | 40 |
Market Cap. Distribution
EcoR1 Capital, LLC has about 13.2% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- SMALL-CAP
- MID-CAP
- LARGE-CAP
- MICRO-CAP
| Category | % |
|---|---|
| UNALLOCATED | 40 |
| SMALL-CAP | 25.4 |
| MID-CAP | 19.7 |
| LARGE-CAP | 13.2 |
| MICRO-CAP | 1.1 |
Stocks belong to which Index?
About 62.1% of the stocks held by EcoR1 Capital, LLC either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
| Index | % |
|---|---|
| RUSSELL 2000 | 62.1 |
| Others | 37.9 |
EcoR1 Capital, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of EcoR1 Capital, LLC
EcoR1 Capital, LLC has 28 stocks in it's portfolio. About 84.6% of the portfolio is in top 10 stocks. ORIC proved to be the most loss making stock for the portfolio. ZYME was the most profitable stock for EcoR1 Capital, LLC last quarter.
Last Reported on: 17 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ALKS | alkermes plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ANAB | anaptysbio inc | 17.33 | 7,880,090 | 382,027,000 | unchanged | 0.00 | ||
| APLS | apellis pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AQST | aquestive therapeutics inc | 0.77 | 2,625,000 | 16,957,500 | unchanged | 0.00 | ||
| ATRA | atara biotherapeutics inc | 0.47 | 573,183 | 10,368,900 | unchanged | 0.00 | ||
| CMPS | compass pathways plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CNTA | centessa pharmaceuticals plc | 3.54 | 3,115,000 | 77,906,200 | added | 466 | ||
| CRNX | crinetics pharmaceuticals in | 9.06 | 4,288,120 | 199,612,000 | unchanged | 0.00 | ||
| CRSP | crispr therapeutics ag | 3.31 | 1,389,280 | 72,853,600 | unchanged | 0.00 | ||
| EOLS | evolus inc | 0.20 | 675,000 | 4,488,750 | new | |||
| ETON | eton pharmaceuticals inc | 1.56 | 2,030,540 | 34,336,500 | unchanged | 0.00 | ||
| GLPG | galapagos nv | 2.47 | 1,667,120 | 54,514,800 | unchanged | 0.00 | ||
| IBIO | ibio inc | 0.20 | 2,228,000 | 4,300,040 | new | |||
| IMNM | immunome inc | 2.78 | 2,855,590 | 61,338,100 | reduced | -30.00 | ||
| JAZZ | jazz pharmaceuticals plc | 13.16 | 1,706,470 | 290,100,000 | unchanged | 0.00 | ||
| KURA | kura oncology inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MDGL | madrigal pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MNKD | mannkind corp | 0.43 | 1,660,000 | 9,412,200 | new | |||
| MREO | mereo biopharma group plc | 0.15 | 7,856,470 | 3,273,790 | new | |||
| NUVB | nuvation bio inc | 0.39 | 963,333 | 8,631,460 | unchanged | 0.00 | ||